<?xml version="1.0" encoding="UTF-8"?>
<p id="Par64">The principal investigator will observe adverse events (AEs) and all AEs spontaneously reported by the study subjects. The principal investigator will assess all AEs for seriousness, causality, severity, and for expectedness if the AE is related to the study drug. All AEs will be assessed by the principal investigator as possibly, probably, or definitely related to the study drug and all serious adverse events (SAEs) that occur during the study period will be followed until they are resolved or clearly determined to be due to a patientâ€™s stable or chronic conditions or intercurrent illness. Reporting will follow the filgrastim-mobilized, peripheral blood stem cell donor assessment of NMDP [
 <xref ref-type="bibr" rid="CR23">23</xref>].
</p>
